Press Releases Vivos Therapeutics, Inc.

Equities

VVOS

US92859E2072

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
2.45 ^USD	+6.52%		+17.22%	-80.31%

May. 14	Transcript : Vivos Therapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024
May. 14	Vivos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update	May. 14	AQ
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call	May. 14	AQ
Vivos Therapeutics : Material Event - Form 8-K	May. 06	PU
Vivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical Devices	Apr. 09	AQ
Vivos Therapeutics : rsquo; Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement	Apr. 09	PU
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update	Mar. 28	AQ
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call	Mar. 28	AQ
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds	Feb. 15	AQ
Vivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market Disruptions	Feb. 12	AQ
Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities	Feb. 06	AQ
Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSA	Jan. 08	AQ
Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”	Dec. 11	AQ
Vivos Therapeutics hits major milestone with FDA clearance for treating severe sleep apnea	Nov. 29	AQ
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea	Nov. 29	AQ
Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update	Nov. 14	AQ
Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call	Nov. 09	AQ
Vivos Therapeutics agrees to nationwide distribution deal with in-home respiratory dealer Lincare	Nov. 03	AQ
Vivos Therapeutics Closes $4 Million Private Placement	Nov. 02	AQ
Vivos Therapeutics Announces Pricing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules	23-10-31	AQ
Vivos Therapeutics Announces Reverse Stock Split	23-10-26	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Vivos Therapeutics, Inc.

Equities

VVOS

US92859E2072

Press Releases

Filters